Some people are already relocating clinical trials to jurisdictions whose regulatory environments better match their preferred approach and views of efficacy.

“And they're already seeing a lot of people moving their trials to places where the regulatory environment makes more sense for how things are,”

“how they want to pursue and what people think is efficacious for them.”